Latest Genzyme Stories

NORTH GRADTON, Mass., June 28, 2012 /PRNewswire/ -- Continental Who's Who/- Mary Belmore is recognized by Continental Who's Who as a Pinnacle Professional as a result of 27 Years of Excellence in the field of Healthcare. Mary is the Associate Director of Research and Development Quality with Genzyme (a Sanofi Company). As an associate director of the Genzyme (a Sanofi Company), Ms. Belmore has been with the company for 27 years. She is responsible for overseeing the documentation...

Henri Termeer, Biotech Legend and former President and CEO of Genzyme, To Receive Lifetime Achievement Award; Nominations Now Being Accepted For Medical Care and Research & Science Award Categories DANA POINT, Calif., June 27, 2012 /PRNewswire-USNewswire/ -- Global Genes (www.globalgenes.org) and the R.A.R.E. Project are proud to announce the first annual 'RARE Tribute to Champions of Hope' Gala and Rare and Genetic Disease Patient Advocacy Summit to be held September 27-28,...

SAN DIEGO, June 19, 2012 /PRNewswire/ -- Althea Technologies, a leading provider of development and manufacturing services for biopharmaceutical products, today announced that Dennis Fenton, Ph.D., will chair Althea's Scientific Advisory Board and be appointed as Board Observer. Dr. Fenton brings 35 years of experience in the biotechnology and pharmaceutical industries to this role. Starting his career at Pfizer Central Research, he subsequently joined Amgen at its inception, where...

BOSTON, June 14, 2012 /PRNewswire/ -- Hailing from the same country that produced the first cloned mammal, introduced anesthesia, discovered penicillin and developed the first bionic hand, eight Scottish companies will meet with executives of Boston's top pharmaceutical and biotechnology companies on June 14-15 in hopes of securing new investment for Scotland's thriving life sciences industry. Led by Scottish Development International (SDI), the government's economic development and...

GAITHERSBURG, Md., May 31, 2012 /PRNewswire/ -- Zyngenia, Inc., a biopharmaceutical company developing Zybodies (next-generation multi-specific antibody-based drugs) in oncology and immunology, announced today that it has appointed Frank Hsu, M.D., as Chief Medical Officer (CMO) and a member of its executive team. Dr. Hsu is a medical oncologist and immunologist with deep academic and industry clinical research experience who most recently served as Senior Medical Director at...

CARLSBAD, Calif., May 30, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June 5, 2012 at 1:20 p.m. PT at the Terranea Resort in Rancho Palos Verdes, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site,...

CARLSBAD, Calif., May 8, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported a pro forma net operating loss (NOL) of $16.2 million for the first quarter of 2012 compared to a pro forma NOL of $13.4 million for the same period in 2011. The Company ended the first quarter of 2012 with nearly $334 million in cash. "Already in 2012, we have had multiple important accomplishments. Our partners at Genzyme submitted the KYNAMRO(TM) new drug application (NDA)...

PARIS, April 27, 2012 /PRNewswire/ -- (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Q1 2012 Change on a Change at constant reported basis exchange rates -------------- -------------- Net sales euro 8,511m +9.4% +7.0% Business net income(1) euro 2,442m +12.5% +8.4%...

CANTON, Mass., March 27, 2012 /PRNewswire/ -- Today MassBio members elected Geoff MacKay, president & CEO of regenerative medicine leader Organogenesis Inc., as chairman of the board of directors at the 2012 MassBio Annual Meeting. (Photo: http://photos.prnewswire.com/prnh/20120327/NE76866) During this year's meeting, MassBio members also elected three new board members: Caren Arnstein, senior vice president and Head of Communications for Genzyme, James Hoyes, President of...

CARLSBAD, Calif., March 22, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast: Error occurred while generating ASCII Content for table ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular,...